Race against time: can an HIV drug slow a fatal brain disease?
NCT ID NCT07482085
Summary
This study is testing whether a drug called efavirenz, currently used for HIV, can help people with Creutzfeldt-Jakob Disease (CJD) live longer. It will involve 246 adults with CJD across 21 hospitals. Half will receive the drug and half will receive a placebo (a dummy pill) to see if the drug safely extends survival and slows the loss of daily abilities.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CREUTZFELDT-JAKOB DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xuanwu Hospital, Capital Medical University
Beijing, 100053, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.